Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial
Anticancer Research · 2024
DOI: 10.21873/anticanres.16795 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Anticancer Research, 2024. Verfasst von Molly K Tate und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.S.A. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery, Metformin. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND/AIM: Non-small cell lung cancer (NSCLC) is increasingly detected in early stages and there is interest in improving outcomes with stereotactic body radiotherapy (SBRT). As metformin affects NSCLC signaling pathways, it might alter the metabolism of NSCLC treated with SBRT. This study investigated the long-term outcomes of a phase II clinical trial evaluating metformin in conjunction with SBRT for early-stage NSCLC. PATIENTS AND METHODS: The trial evaluated patients with American Joint Commission on Cancer (AJCC) 7th edition Stage I-II, cT1-T2N0M0 NSCLC who were randomized 6:1 to receive metformin versus placebo in conjunction with SBRT. The outcomes analyzed included local failure (LF), progression-free survival (PFS), overall survival (OS), and Common Terminology Criteria for Adverse Events (CTCAE) version 4 toxicities. RESULTS: There were 14 patients randomized to the metformin arm and one to the placebo. Median follow-up was four years. In the metformin group, the median PFS was 4.65 years [95% confidence interval (CI)=0.31-5.93] and median survival was 4.97 years (95%CI=3.05-4.61). Five year PFS was 27.8% (95%CI=5.3-57.3%) and OS was 46.0% (95%CI=16.0-71.9%). The one patient randomized to placebo was alive and without progression at five years. There were no LFs in the primary SBRT treatment volumes and no CTCAE version 4 Grade ≥3 adverse events. CONCLUSION: Outcomes of SBRT and metformin for early-stage NSCLC were similar to historic controls. These findings along with the results of the NRG-LU001 and OCOG randomized trials do not support the therapeutic use of metformin for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.S.A.
- Department of Biostatistics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.S.A.
- Department of Radiation Oncology, Hillman Cancer Center, University of Pittsburg Medical Center, Pittsburg, PA, U.S.A.
- Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.S.A.; sgchun@mdanderson.org.
Förderung
- NCI NIH HHS
Zitieren
APA
Tate, M. K., Hernandez, M., Chang, J. Y., Lin, S. H., Liao, Z., Koshy, S. M., Skinner, H. D., & Chun, S. G. (2024). Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Research. https://doi.org/10.21873/anticanres.16795
Vancouver
Tate MK, Hernandez M, Chang JY, Lin SH, Liao Z, Koshy SM, et al. Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Research. 2024. doi:10.21873/anticanres.16795
BibTeX
@article{Tate2024,
author = {Tate, Molly K and Hernandez, Mike and Chang, Joe Y and Lin, Steven H and Liao, Zhongxing and Koshy, Suja M and Skinner, Heath D and Chun, Stephen G},
title = {Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.16795}
}
EUVIMED